Oribact Mixture Suspension
Sulphamethoxazole + Trimethoprim (Co-trimoxazole)
"200mg, 40mg/5ml"
Orion Pharmaceutical Co.
| Pack size | 100ml Bottle |
|---|---|
| Dispensing mode | POM |
| Source | FINLAND |
| Agent | AL HAYAT PHARMACEUTICALS |
| Retail Price | 17.50 AED |
Available as:
Indications
Oribact Mixture Suspension is used for:
Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias
Adult Dose
Oral
Acute exacerbations of chronic bronchitis ; Acute otitis media; Urinary tract infections, GI infections; Resp and urinary tract infections; Susceptible infections
Adult:
Tablet : 2 tablet of 480mg twice daily. In severe cases, 3 times/day.
DS Tablet : 1 tablet (960mg) twice daily.
Suspension : 1-2 teaspoonful twice daily.
Pneumocystis (carinii) jiroveci pneumonia
Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days.
Prophylaxis of Pneumocystis (carinii) jiroveci pneumonia
960 mg once daily for 7 days; 960 mg once daily 3 times wkly on alternate days; or 960 mg bid 3 times wkly on alternate days.
Infection prophylaxis in AIDS patients
960 mg/day.
Hepatic impairment: Severe: Contraindicated.
Child Dose
Child:
Oral
8–10 mg TMP/kg/day q12h
2 mg TMP/kg/day for UTI prophylaxis q24h
15–20 mg TMP/kg/day for Pneumocystis (carinii) jiroveci pneumonia treatment q6–8h
150 mg TMP/m2/day, OR 5 mg TMP/kg/day for Pneumocystis (carinii) jiroveci pneumonia prophylaxis q12h, 3 times a week OR q24h
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<15 Not recommended.
15-30 Half the standard dose.
Administration
Contra Indications
Known hypersensitivity to trimethoprim or sulfonamides; severe hepatic failure or marked liver parenchymal damage, jaundice; serious haematological disorders and porphyria; severe renal insufficiency where repeated measurements of the plasma concentration cannot be performed; history of drug-induced immune thrombocytopenia w/ use of trimethoprim and/or sulfonamides; megaloblastic anaemia due to folate deficiency. Neonates <6 wk, except for the treatment/prophylaxis of P. jiroveci in infants >4 wk. Treatment of Group A β-haemolytic streptococcia. Pregnancy, esp in the period prior to birth. Concomitant use w/ clozapine. Concomitant use w/ leucovorin for the treatment of P. jiroveci in HIV positive patients.
Precautions
Patient w/ severe allergy, bronchial asthma, thyroid dysfunction. Renal and mild to moderate hepatic impairment. Lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor CBC, serum K, creatinine, BUN.
Pregnancy-Lactation
Interactions
Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.
Potentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
Adverse Effects
Side effects of Sulphamethoxazole + Trimethoprim (Co-trimoxazole) :
Allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like syndrome, generalised allergic reactions, generalised skin eruptions, photosensitivity, conjunctival and scleral inj, pruritus, urticaria, rash, periarteritis nodosa, SLE; elevated serum transaminase and bilirubin, pseudomembranous enterocolitis, pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhoea, anorexia; renal failure, interstitial nephritis, elevated BUN and serum creatinine, toxic nephrosis w/ oliguria and anuria; hyperkalaemia; aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache; hallucinations, depression, apathy, nervousness; dieresis, hypoglycaemia; arthralgia, myalgia; rhabdomyolysis; cough, shortness of breath, pulmonary infiltrates; weakness, fatigue, insomnia; QT prolongation, haemolysis, impaired phenylalanine metabolism.
Potentially Fatal: Severe skin, hepatic and blood disorders, aplastic anaemia, hypersensitivity of the resp tract; Stevens-Johnson syndrome, toxic epidermal necrolysis; Clostridium difficile-associated diarrhoea; severe and symptomatic hyponatraemia.
Mechanism of Action
Co-trimoxazole exhibits the synergistic actions of its components (sulfamethoxazole and trimethoprim) by 10-fold. Sulfamethoxazole inhibits dihydrofolic acid formation from PABA, thus interfering with synthesis and growth of bacterial folic acid. Trimethoprim inhibits enzymes folic acid pathway, preventing the reaction of the dihydrolic acid to tetrahydrofolate. Co-trimoxazole possesses bactericidal effects against E coli, Klebsiella spp, Enterobacter spp, M morganii, P mirabilis, P vulgaris, H influenzae, Strep pneumoniae, Pneumocystis (carinii) jiroveci, Cyclospora spp.
Note
Oribact Mixture "200mg, 40mg/5ml" Suspension manufactured by Orion Pharmaceutical Co.. Its generic name is Sulphamethoxazole + Trimethoprim (Co-trimoxazole). Oribact Mixture is availble in United Arab Emirates.
Farmaco UAE drug index information on Oribact Mixture Suspension is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Sulphamethoxazole + Trimethoprim (Co-trimoxazole) :
Suspension
Septrin (Paediatric)
"200mg, 40mg/5ml"
ASPEN BAD OLDESLOE GmbH
Suspension
Septrin (Paediatric)
"200mg, 40mg/5ml"
ASPEN BAD OLDESLOE GmbH
Tablets
Septrin
"400mg, 80mg"
ASPEN BAD OLDESLOE GmbH
Tablets
Septrin
"400mg, 80mg"
ASPEN BAD OLDESLOE GmbH
Tablets
Septazole 400mg/80mg
400mg/80mg
ALEXANDRIA CO. FOR PHARMACEUTICALS